TY - JOUR
T1 - Italian real life experience with brentuximab vedotin
T2 - Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
AU - Pellegrini, Cinzia
AU - Broccoli, Alessandro
AU - Pulsoni, Alessandro
AU - Rigacci, Luigi
AU - Patti, Caterina
AU - Gini, Guido
AU - Mannina, Donato
AU - Tani, Monica
AU - Rusconi, Chiara
AU - Romano, Alessandra
AU - Vanazzi, Anna
AU - Botto, Barbara
AU - Santoro, Armando
AU - Hoaus, Stefan
AU - Rigolin, Gian Matteo
AU - Musto, Pellegrino
AU - Mazza, Patrizio
AU - Molica, Stefano
AU - Corradini, Paolo
AU - Fama, Angelo
AU - Gaudio, Francesco
AU - Merli, Michele
AU - Ronconi, Fioravante
AU - Gritti, Giuseppe
AU - Vallisa, Daniele
AU - Tosi, Patrizia
AU - Liberati, Anna Marina
AU - Pinto, Antonello
AU - Pavone, Vincenzo
AU - Gherlinzoni, Filippo
AU - Bianchi, Maria Paola
AU - Volpetti, Stefano
AU - Trentin, Livio
AU - Goldaniga, Maria Cecilia
AU - Bonfichi, Maurizio
AU - Renzo, Amalia De
AU - Schiavotto, Corrado
AU - Spina, Michele
AU - Carella, Angelo Michele
AU - Stefoni, Vittorio
AU - Argnani, Lisa
AU - Zinzani, Pier Luigi
PY - 2017
Y1 - 2017
N2 - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
AB - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
KW - Brentuximab vedotin
KW - Hodgkin's lymphoma
KW - Long-term response
KW - Real life
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85032644728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032644728&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.18114
DO - 10.18632/oncotarget.18114
M3 - Article
AN - SCOPUS:85032644728
SN - 1949-2553
VL - 8
SP - 91703
EP - 91710
JO - Oncotarget
JF - Oncotarget
IS - 53
ER -